Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 67

Similar articles for PubMed (Select 12517773)

1.
2.
3.

UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation.

Sugiyama K, Shimizu M, Akiyama T, Tamaoki T, Yamaguchi K, Takahashi R, Eastman A, Akinaga S.

Int J Cancer. 2000 Mar 1;85(5):703-9.

PMID:
10699952
4.

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A.

Cancer Res. 2000 Feb 1;60(3):566-72.

5.
6.

PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells.

Aaltonen V, Koivunen J, Laato M, Peltonen J.

Cancer Lett. 2007 Aug 8;253(1):97-107. Epub 2007 Feb 22.

PMID:
17320279
7.
8.

Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest.

Jones CB, Clements MK, Wasi S, Daoud SS.

Cancer Chemother Pharmacol. 2000;45(3):252-8.

PMID:
10663644
10.
11.

[Protein kinase C inhibitor Gö6976 sensitizes arsenic trioxide-induced cell apoptosis in chronic myeloid leukemic cells].

Wu XF, Chen ZC, Liu ZP, You Y, Li WM, Zou P.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Feb;13(1):100-3. Chinese.

PMID:
15748445
13.
14.

Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.

Qamar L, Davis R, Anwar A, Behbakht K.

Gynecol Oncol. 2008 Sep;110(3):425-31. doi: 10.1016/j.ygyno.2008.04.039. Epub 2008 Jul 10.

PMID:
18619662
15.

Inhibition of CHK1 kinase by Gö6976 converts 8-chloro-adenosine-induced G2/M arrest into S arrest in human myelocytic leukemia K562 cells.

Jia XZ, Yang SY, Zhou J, Li SY, Ni JH, An GS, Jia HT.

Biochem Pharmacol. 2009 Mar 1;77(5):770-80. doi: 10.1016/j.bcp.2008.11.008. Epub 2008 Nov 18.

PMID:
19059218
16.
18.
19.

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.

Grandage VL, Everington T, Linch DC, Khwaja A.

Br J Haematol. 2006 Nov;135(3):303-16. Epub 2006 Sep 4.

PMID:
16956345
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk